ICM-012
/ iCoat Medical
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
April 03, 2025
A Trial to Assess Efficacy and Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/ml to Improve Its Function in Recipients of DCD Kidneys
(clinicaltrials.gov)
- P2/3 | N=200 | Not yet recruiting | Sponsor: iCoat Medical AB | Trial completion date: Jul 2026 ➔ Dec 2026 | Initiation date: Jan 2025 ➔ Sep 2025 | Trial primary completion date: Jul 2026 ➔ Dec 2026
Trial completion date • Trial initiation date • Trial primary completion date • Cardiovascular • Reperfusion Injury • Transplantation
October 12, 2024
First-in-Human Phase 2a (ATMIRe) Trial of Ex Vivo Allograft Treatment with iCM012 to Mitigate Ischemia-Reperfusion Injury in Kidney Transplantation
(KIDNEY WEEK 2024)
- P1/2 | "iCM012 demonstrated a favorable safety profile and showed promising efficacy in mitigating IRI and preserving allograft function within a 12-month follow-up. These findings strongly support further investigation in larger, multicenter trials to confirm its therapeutic potential in kidney transplantation."
P1 data • P2a data • Preclinical • Cardiovascular • Inflammation • Reperfusion Injury • Transplantation • CST3 • FABP1 • IL18 • KIM1
June 04, 2024
FIH Phase I/IIa Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation
(clinicaltrials.gov)
- P1/2 | N=18 | Completed | Sponsor: iCoat Medical AB | Active, not recruiting ➔ Completed
Trial completion • Cardiovascular • Reperfusion Injury • Transplantation
December 05, 2023
FIH Phase I/IIa Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation
(clinicaltrials.gov)
- P1/2 | N=18 | Active, not recruiting | Sponsor: iCoat Medical AB | Phase classification: P1 ➔ P1/2
Phase classification • Cardiovascular • Reperfusion Injury • Transplantation
September 13, 2023
FIH (First in Human) Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation
(clinicaltrials.gov)
- P1 | N=18 | Active, not recruiting | Sponsor: iCoat Medical AB | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2023 ➔ May 2024 | Trial primary completion date: Apr 2023 ➔ Jul 2023
Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Reperfusion Injury • Transplantation
1 to 5
Of
5
Go to page
1